Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price objective increased by Barclays from $145.00 to $160.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Barclays‘s price objective indicates a potential downside of 6.04% from the company’s previous close.
Several other research firms have also commented on GILD. BMO Capital Markets reaffirmed an “outperform” rating and set a $184.00 price target on shares of Gilead Sciences in a research report on Friday, October 30th. Royal Bank Of Canada raised their price objective on shares of Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a report on Friday, October 30th. HSBC boosted their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Zacks Research cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 29th. Finally, Weiss Ratings raised shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $171.63.
Check Out Our Latest Stock Analysis on GILD
Gilead Sciences Stock Performance
Shares of GILD traded up $2.21 during trading hours on Monday, hitting $170.28. The stock had a trading volume of 627,308 shares, compared to its average volume of 6,771,567. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. Gilead Sciences has a 12 month low of $116.88 and a 12 month high of $176.58. The firm has a market capitalization of $211.21 billion, a PE ratio of -53.95 and a beta of 0.35. The stock has a fifty day moving average price of $155.10 and a 200 day moving average price of $141.80.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. The company had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. Gilead Sciences’s revenue was up 6.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.47 earnings per share. Analysts anticipate that Gilead Sciences will post -0.97 EPS for the current year.
Insider Activity at Gilead Sciences
In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the sale, the insider directly owned 113,684 shares in the company, valued at approximately $17,759,714.48. The trade was a 2.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $145.02, for a total transaction of $725,100.00. Following the transaction, the director directly owned 10,066 shares of the company’s stock, valued at $1,459,771.32. This trade represents a 33.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 211,709 shares of company stock valued at $35,234,427 in the last ninety days. Corporate insiders own 0.30% of the company’s stock.
Hedge Funds Weigh In On Gilead Sciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Gilead Sciences during the 2nd quarter valued at $15,393,785,000. State Street Corp boosted its position in shares of Gilead Sciences by 2.3% in the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after purchasing an additional 1,357,967 shares in the last quarter. Amundi grew its stake in Gilead Sciences by 10.7% during the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after buying an additional 1,018,976 shares during the last quarter. Legal & General Group Plc purchased a new position in Gilead Sciences during the 2nd quarter worth $1,316,606,000. Finally, Deutsche Bank AG purchased a new position in Gilead Sciences during the 2nd quarter worth $918,387,000. 83.67% of the stock is owned by institutional investors.
Key Headlines Impacting Gilead Sciences
These are some of the GILD headlines that stood out recently:
- Positive Sentiment: Gilead’s earnings call was characterized as signaling broad growth momentum, offering a positive business outlook, though the provided article details do not specify which products or results drove that assessment. Gilead Sciences Earnings Call Signals Broad Growth Momentum
- Neutral Sentiment: Gilead appeared in an article about dividend stocks for retirees, but the item supplied no Gilead-specific change to its dividend or outlook. A separate article noted the stock’s strong relative performance over the past year, while discussing weaker longer-term returns. Dividend Stocks for Retirees Gilead’s Relative Performance
- Negative Sentiment: Zacks Research’s latest headline points to lower earnings expectations. Its detailed estimate changes were mixed, but included cuts to FY2026 EPS (to -$0.86 from -$0.65) and Q4 2026 EPS (to $1.31 from $2.14); it maintained a Hold rating. These downward revisions may weigh on sentiment. Zacks Forecasts Lower Earnings Zacks Estimate Revisions
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Recommended Stories
- Five stocks we like better than Gilead Sciences
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
